Fig. 3
From: ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia
Caspase activity upon ULK1 inhibition in FLT3-ITD AML cells. a Cleaved caspase-3 and -9 and PARP levels were examined after treatment of MV4;11 cells and U937 cells with ULK1 inhibitors (MRT 68921; 2.5 μM, SBI-0206965; 5 μM) for 48 h by western blot analysis. α-Tubulin was used as a loading control. b After pre-treatment with the pan-caspase inhibitor z-VAD-fmk (20 μM), cells were treated with ULK1 inhibitors (MRT 68921; 2.5 μM, SBI-0206965; 5 μM). The fraction of apoptotic cells in MV4;11 cells and U937 cells was analyzed by flow cytometry based on Annexin-V/PI exclusion. c The MMP was quantified by measuring membrane potential-sensitive dye (DiOC6) intensity in MV4;11 and U937 cells after treatment of ULK1 inhibitors (MRT 68921; 2.5 μM, SBI-0206965; 5 μM). CTL, control. NS, not significant